Patents by Inventor Michael Charles Hewitt
Michael Charles Hewitt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240358675Abstract: Provided herein are multicyclic compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.Type: ApplicationFiled: January 18, 2024Publication date: October 31, 2024Applicants: Sumitomo Pharma America, Inc., PGI Drug Discovery LLCInventors: Liming SHAO, John Emmerson CAMPBELL, Michael Charles HEWITT, Una CAMPBELL, Taleen G. HANANIA
-
Publication number: 20220387382Abstract: Provided herein are multicyclic compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.Type: ApplicationFiled: January 13, 2022Publication date: December 8, 2022Applicants: Sunovion Pharmaceuticals Inc., PGI Drug Discovery LLCInventors: Liming SHAO, John Emmerson CAMPBELL, Michael Charles HEWITT, Una CAMPBELL, Taleen G. HANANIA
-
Publication number: 20220267323Abstract: Provided herein are synthetic methods for the preparation of compounds having the Formula: (I) and (I?) and salts thereof.Type: ApplicationFiled: July 23, 2020Publication date: August 25, 2022Inventors: Nathan Oliver Fuller, Michael Charles Hewitt, Sylvie M. Asselin, Wayne Douglas Luke
-
Publication number: 20210267938Abstract: Provided herein are multicyclic compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.Type: ApplicationFiled: November 19, 2020Publication date: September 2, 2021Applicants: Sunovion Pharmaceuticals Inc., PGI Drug Discovery LLCInventors: Liming SHAO, John Emmerson CAMPBELL, Michael Charles HEWITT, Una CAMPBELL, Taleen G. HANANIA
-
Patent number: 10894033Abstract: Provided herein are multicyclic compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.Type: GrantFiled: February 14, 2020Date of Patent: January 19, 2021Assignees: Sunovion Pharmaceuticals Inc., PGI Drug Discovery LLCInventors: Liming Shao, John Emmerson Campbell, Michael Charles Hewitt, Una Campbell, Taleen G. Hanania
-
Publication number: 20200323819Abstract: Provided herein are multicyclic compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.Type: ApplicationFiled: February 14, 2020Publication date: October 15, 2020Applicants: Sunovion Pharmaceuticals Inc., PGI Drug Discovery LLCInventors: Liming SHAO, John Emmerson CAMPBELL, Michael Charles HEWITT, Una CAMPBELL, Taleen G. HANANIA
-
Patent number: 10570156Abstract: Provided herein are cyclic nucleotide phosphodiesterase inhibitors of Formula (I) of claim 1, and pharmaceutical compositions thereof, useful for the treatment of, for example, central nervous system and metabolic diseases and disorder.Type: GrantFiled: November 20, 2017Date of Patent: February 25, 2020Assignee: SUNOVION PHARMACEUTICALS INC.Inventors: John Emmerson Campbell, Philip Wendell Jones, Michael Charles Hewitt
-
Patent number: 10562916Abstract: Provided herein are cyclic nucleotide phosphodiesterase inhibitors, and pharmaceutical compositions thereof, useful for the treatment of, for example, central nervous system and metabolic diseases and disorder.Type: GrantFiled: October 19, 2017Date of Patent: February 18, 2020Assignee: Sunovion Pharmaceuticals, Inc.Inventors: John Emmerson Campbell, Michael Charles Hewitt, Philip Xinhe Jones, Linghong Xie
-
Patent number: 10562878Abstract: The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.Type: GrantFiled: December 8, 2017Date of Patent: February 18, 2020Assignee: SUNOVION PHARAMCEUTICALS INC.Inventors: Liming Shao, Fengjiang Wang, Scott Christopher Malcolm, Michael Charles Hewitt, Larry R. Bush, Jianguo Ma, Mark A. Varney, Una Campbell, Sharon Rae Engel, Larry Wendell Hardy, Patrick Koch, John E. Campell
-
Patent number: 10457640Abstract: Provided herein are synthetic methods for the preparation of EZH2 inhibitors.Type: GrantFiled: October 18, 2017Date of Patent: October 29, 2019Assignee: Constellation Pharmaceuticals, Inc.Inventors: Rishi G. Vaswani, Michael Charles Hewitt
-
Publication number: 20190233375Abstract: Provided herein are synthetic methods for the preparation of EZH2 inhibitors.Type: ApplicationFiled: October 18, 2017Publication date: August 1, 2019Inventors: Rishi G. Vaswani, Michael Charles Hewitt
-
Publication number: 20190125722Abstract: Provided herein are multicyclic compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.Type: ApplicationFiled: August 30, 2018Publication date: May 2, 2019Applicants: Sunovion Pharmaceuticals Inc., PGI Drug Discovery LLCInventors: Liming SHAO, John Emmerson CAMPBELL, Michael Charles HEWITT, Una CAMPBELL, Taleen G. HANANIA
-
Patent number: 10258603Abstract: The present invention relates to compounds of formula (I): and to salts thereof, wherein R1, R2, Rc, and Rd have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of bromodomains. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various bromodomain-mediated disorders.Type: GrantFiled: May 10, 2017Date of Patent: April 16, 2019Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.Inventors: Brian K. Albrecht, Steven F. Bellon, Daniel J. Burdick, Alexandre Cote, Terry Crawford, Les A. Dakin, Vickie Hsiao-Wei Tsui, Michael Charles Hewitt, Yves LeBlanc, Steven R. Magnuson, Christopher G. Nasveschuk, F. Anthony Romero, Yong Tang, Alexander M. Taylor, Shumei Wang
-
Patent number: 10206931Abstract: The present invention relates to compounds of formula (I): and to salts thereof, wherein A has any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.Type: GrantFiled: April 7, 2017Date of Patent: February 19, 2019Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.Inventors: F. Anthony Romero, Steven R. Magnuson, Richard Pastor, Vickie Hsiao-Wei Tsui, Jeremy Murray, Terry Crawford, Daniel J. Burdick, Brian K. Albrecht, Alexandre Cote, Alexander M. Taylor, Christopher G. Nasveschuck, Yves LeBlanc, Michael Charles Hewitt, Kwong Wah Lai, Kevin Chen
-
Patent number: 10183009Abstract: The present invention relates to compounds of formula (I): and to salts thereof, wherein R1, R2, and Q have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of bromodomains. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various bromodomain-mediated disorders.Type: GrantFiled: May 10, 2017Date of Patent: January 22, 2019Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.Inventors: Brian K. Albrecht, Steven F. Bellon, Daniel J. Burdick, Alexandre Cote, Terry Crawford, Les A. Dakin, Vickie Hsiao-Wei Tsui, Michael Charles Hewitt, Yves LeBlanc, Steven R. Magnuson, Christopher G. Nasveschuk, F. Anthony Romero, Yong Tang, Alexander M. Taylor, Shumei Wang
-
Patent number: 10150767Abstract: The present invention relates to compounds of formula (I): and to salts thereof, wherein R1, R2, and Q have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of bromodomains. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various bromodomain-mediated disorders.Type: GrantFiled: May 10, 2017Date of Patent: December 11, 2018Assignees: Genentech, Inc., Constellation Pharmaceuticals Inc.Inventors: Brian K. Albrecht, Steven F. Bellon, Daniel J. Burdick, Alexandre Cote, Terry Crawford, Les A. Dakin, Vickie Hsiao-Wei Tsui, Michael Charles Hewitt, Yves LeBlanc, Steven R. Magnuson, Christopher G. Nasveschuk, Anthony F. Romero, Yong Tang, Alexander M. Taylor, Shumei Wang
-
Patent number: 10085968Abstract: Provided herein are multicyclic compounds of formula (IVa), shown below, wherein R1, R2, R3, R4, R5, R6, R7, m, and n are defined herein elsewhere, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.Type: GrantFiled: November 24, 2015Date of Patent: October 2, 2018Assignees: Sunovion Pharmaceuticals Inc., PGI Drug Discovery LLC.Inventors: Liming Shao, John Emmerson Campbell, Michael Charles Hewitt, Una Campbell, Taleen G. Hanania
-
Publication number: 20180230120Abstract: The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.Type: ApplicationFiled: December 8, 2017Publication date: August 16, 2018Inventors: Liming SHAO, Fengjiang WANG, Scott Christopher MALCOLM, Michael Charles HEWITT, Larry R. BUSH, Jianguo MA, Mark A. VARNEY, Una CAMPBELL, Sharon Rae ENGEL, Larry Wendell HARDY, Patrick KOCH, John E. CAMPELL
-
Patent number: 9925197Abstract: The present invention relates to compounds useful as inhibitors of bromodomain-containing proteins. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.Type: GrantFiled: September 27, 2016Date of Patent: March 27, 2018Assignee: Constellation Pharmaceuticals, Inc.Inventors: Brian K. Albrecht, Michael Charles Hewitt, Victor S. Gehling, Rishi G. Vaswani
-
Publication number: 20180072759Abstract: Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes.Type: ApplicationFiled: November 20, 2017Publication date: March 15, 2018Inventors: John Emmerson Campbell, Philip Wendell Jones, Michael Charles Hewitt